Myelodysplastic syndrome and histone deacetylase inhibitors: To be or not to be acetylated?

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Neureiter, Daniel ^b   Stintzing, Sebastian ^a   Kemmerling, Ralf ^b   Kiesslich, Tobias ^b   Alinger, Beate ^b   Ocker, Matthias ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Salzburger Landeskliniken   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BELINOSTAT; BUTYRIC ACID; CYCLOSPORIN; DEFERASIROX; DEFEROXAMINE; DEPSIPEPTIDE; ENTINOSTAT; ERYTHROPOIETIN; GYRASE INHIBITOR; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANOBINOSTAT; PYROXAMIDE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; ROMIDEPSIN; TACEDINALINE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; HISTONE DEACETYLASE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ANEMIA; APOPTOSIS; ASTHENIA; BRAIN TOXICITY; CARCINOGENESIS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DEPRESSION; CHELATION THERAPY; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONFUSION; CONTINUOUS INFUSION; DIARRHEA; DNA METHYLATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; EPIGENETICS; FATIGUE; FEVER; GENE MUTATION; GENE SILENCING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; INFECTION; INJECTION SITE REACTION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; MYELOID DIFFERENTIATION SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHENOTYPE; PHYSICAL ACTIVITY; PROGNOSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SOMNOLENCE; STEM CELL; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; TUMOR MICROENVIRONMENT; TYPHLITIS; VOMITING; ACETYLATION; ANIMAL; DRUG EFFECT; METABOLISM;

ACETYLATION; ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 79959348192     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/214143     Document Type: Review

References (154)

1. Bennett J. M., Catovsky D., Daniel M. T., Proposals for the classification of the myelodysplastic syndromes British Journal of Haematology 1982 51 2 189 199 (Pubitemid 12073508)
2. Cazzola M., Malcovati L., Myelodysplastic syndromescoping with ineffective hematopoiesis New England Journal of Medicine 2005 352 6 536 538
3. Vardiman J. W., Thiele J., Arber D. A., Brunning R. D., Borowitz M. J., Porwit A., Harris N. L., Le Beau M. M., Hellstrm-Lindberg E., Tefferi A., Bloomfield C. D., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 2009 114 5 937 951
4. Strom S. S., Vlez-Bravo V., Estey E. H., Epidemiology of myelodysplastic syndromes Seminars in Hematology 2008 45 1 8 13
5. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L., The incidence of secondary leukemias Haematologica 1999 84 10 937 945 (Pubitemid 29516926)
6. Corey S. J., Minden M. D., Barber D. L., Kantarjian H., Wang J. C. Y., Schimmer A. D., Myelodysplastic syndromes: the complexity of stem-cell diseases Nature Reviews Cancer 2007 7 2 118 129 (Pubitemid 46164747)
7. Bernasconi P., Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctionsa review British Journal of Haematology 2008 142 5 695 708
8. Raskind W. H., Tirumali N., Jacobson R., Evidence for a multistep pathogenesis of a myelodysplastic syndrome Blood 1984 63 6 1318 1323 (Pubitemid 14120375)
9. Rosenfeld C., List A., A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies Leukemia 2000 14 1 2 8 (Pubitemid 30068366)
10. Hirai H., Molecular mechanisms of myelodysplastic syndrome Japanese Journal of Clinical Oncology 2003 33 4 153 160 (Pubitemid 43102857)
11. Nolte F., Hofmann W. K., Myelodysplastic syndromes: molecular pathogenesis and genomic changes Annals of Hematology 2008 87 10 777 795
12. Greenberg P., Cox C., LeBeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J., International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89 6 2079 2088 (Pubitemid 27132124)
13. Greenberg P. L., Current therapeutic approaches for patients with myelodysplastic syndromes British Journal of Haematology 2010 150 2 131 143
14. Batty N., Malouf G. G., Issa J. P. J., Histone deacetylase inhibitors as anti-neoplastic agents Cancer Letters 2009 280 2 192 200
15. Griffiths E. A., Gore S. D., DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes Seminars in Hematology 2008 45 1 23 30
16. Issa J. P., Epigenetic changes in the myelodysplastic syndrome Hematology/Oncology Clinics of North America 2010 24 2 317 330
17. Kuendgen A., Lbbert M., Current status of epigenetic treatment in myelodysplastic syndromes Annals of Hematology 2008 87 8 601 611
18. Nimer S. D., Myelodysplastic syndromes Blood 2008 111 10 4841 4851
19. Vallesp T., Imbert M., Mecucci C., Preudhomme C., Fenaux P., Diagnosis, classification, and cytogenetics of myelodysplastic syndromes Haematologica 1998 83 3 258 275 (Pubitemid 28209132)
20. Heaney M. L., Golde D. W., Myelodysplasia New England Journal of Medicine 1999 340 21 1649 1660 (Pubitemid 29249435)
21. Schmitt-Graeff A., Mattern D., Khler H., Hezel J., Lbbert M., Myelodysplastic syndromes: aspects of hematopathologic diagnosis Pathologe 2000 21 1 1 15 (Pubitemid 30163192)
22. Steensma D. P., The changing classification of myelodysplastic syndromes: what's in a name? HematologyAmerican Society of Hematology. Education Program 2009 645 655
23. Malcovati L., Germing U., Kuendgen A., Della Porta M. G., Pascutto C., Invernizzi R., Giagounidis A., Hildebrandt B., Bernasconi P., Knipp S., Strupp C., Lazzarino M., Aul C., Cazzola M., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes Journal of Clinical Oncology 2007 25 23 3503 3510 (Pubitemid 47315575)
24. Mufti G. J., Pathobiology, classification, and diagnosis of myelodysplastic syndrome Best Practice and Research: Clinical Haematology 2004 17 4 543 557 (Pubitemid 39378186)
25. Pedersen-Bjergaard J., Andersen M. K., Christiansen D. H., Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation Blood 2000 95 11 3273 3279 (Pubitemid 30428453)
26. Giles F. J., Koeffler H. P., Secondary myelodysplastic syndromes and leukemias Current Opinion in Hematology 1994 1 4 256 260
27. Pedersen-Bjergaard J., Andersen M. K., Christiansen D. H., Nerlov C., Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia Blood 2002 99 6 1909 1912 (Pubitemid 34525468)
28. Aul C., Germing U., Gattermann N., Minning H., Increasing incidence of myelodysplastic syndromes: real or fictitious? Leukemia Research 1998 22 1 93 100 (Pubitemid 28167552)
29. Aul C., Gattermann N., Schneider W., Age-related incidence and other epidemiological aspects of myelodysplastic syndromes British Journal of Haematology 1992 82 2 358 367
30. Radlund A., Thiede T., Hansen S., Carlsson M., Engquist L., Incidence of myelodysplastic syndromes in a Swedish population European Journal of Haematology 1995 54 3 153 156
31. Williamson P. J., Kruger A. R., Reynolds P. I., Hamblin T. J., Oscier D. G., Establishing the incidence of myelodysplastic syndrome British Journal of Haematology 1994 87 4 743 745 (Pubitemid 24264646)
32. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarr M. C., Damaj G., Giraudier S., Guerci A., Laurent G., Dombret H., Chomienne C., Ribrag V., Stamatoullas A., Marie J. P., Vekhoff A., Maloisel F., Navarro R., Dreyfus F., Fenaux P., Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 2004 104 2 321 327 (Pubitemid 38900010)
33. Goss T. F., Szende A., Schaefer C., Totten P. J., Knight R., Jdersten M., Hellstrm-Lindberg E., List A. F., Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States Cancer Control 2006 13, supplement 17 25 (Pubitemid 46148106)
34. Greenberg P. L., Cosler L. E., Ferro S. A., Lyman G. H., The costs of drugs used to treat myelodysplastic syndromes following national comprehensive cancer network guidelines Journal of the National Comprehensive Cancer Network 2008 6 9 942 953
35. Kemmerling R., Neureiter D., Faber V., Incidence and other aspects of myelodysplastic syndrome in the Austrian federal state Salzburg Pathology Research and Practice 2007 203 5 392 392
36. Aul C., Bowen D. T., Yoshida Y., Pathogenesis, etiology and epidemiology of myelodysplastic syndromes Haematologica 1998 83 1 71 86 (Pubitemid 28096504)
37. Raza A., Hypothesis: myelodysplastic syndromes may have a viral etiology International Journal of Hematology 1998 68 3 245 256 (Pubitemid 28522550)
38. Mhawech P., Saleem A., Myelodysplastic syndrome: review of the cytogenetic and molecular data Critical Reviews in Oncology/Hematology 2001 40 3 229 238 (Pubitemid 33111069)
39. Olney H. J., Le Beau M. M., The cytogenetics of myelodysplastic syndromes Best Practice and Research: Clinical Haematology 2001 14 3 479 495 (Pubitemid 33019747)
40. List A., Kurtin S., Roe D. J., Buresh A., Mahadevan D., Fuchs D., Rimsza L., Heaton R., Knight R., Zeldis J. B., Efficacy of lenalidomide in myelodysplastic syndromes New England Journal of Medicine 2005 352 6 549 557 (Pubitemid 40204668)
41. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., Powell B., Greenberg P., Thomas D., Stone R., Reeder C., Wride K., Patin J., Schmidt M., Zeldis J., Knight R., Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion New England Journal of Medicine 2006 355 14 1456 1465 (Pubitemid 44511560)
42. O'Keefe C. L., Tiu R., Gondek L. P., Powers J., Theil K. S., Kalaycio M., Lichtin A., Sekeres M. A., Maciejewski J. P., High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes Experimental Hematology 2007 35 2 240 251 (Pubitemid 46135810)
43. Knudson A. G., Hereditary cancer: two hits revisited Journal of Cancer Research and Clinical Oncology 1996 122 3 135 140 (Pubitemid 26076883)
44. Harada H., Harada Y., Tanaka H., Kimura A., Inaba T., Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia Blood 2003 101 2 673 680 (Pubitemid 36077592)
45. Ganly P., Walker L. C., Morris C. M., Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia Leukemia and Lymphoma 2004 45 1 1 10 (Pubitemid 38181387)
46. Song W. J., Sullivan M. G., Legare R. D., Hutchings S., Tan X., Kufrin D., Ratajczak J., Resende I. C., Haworth C., Hock R., Loh M., Felix C., Roy D. C., Busque L., Kurnit D., Willman C., Gewirtz A. M., Speck N. A., Bushweller J. H., Li F. P., Gardiner K., Poncz M., Maris J. M., Gilliland D. G., Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia Nature Genetics 1999 23 2 166 175 (Pubitemid 29455388)
47. Pedersen-Bjergaard J., Christiansen D. H., Desta F., Andersen M. K., Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia Leukemia 2006 20 11 1943 1949 (Pubitemid 44614882)
48. Tennant G. B., Walsh V., Truran L. N., Edwards P., Mills K. I., Burnett A. K., Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia British Journal of Haematology 2000 111 3 853 862 (Pubitemid 32098923)
49. Flores-Figueroa E., Gutirrez-Espndola G., Montesinos J. J., Arana-Trejo R. M., Mayani H., In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome Leukemia Research 2002 26 7 677 686 (Pubitemid 34465704)
50. Stirewalt D. L., Mhyre A. J., Marcondes M., Pogosova-Agadjanyan E., Abbasi N., Radich J. P., Deeg H. J., Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? British Journal of Haematology 2008 140 4 444 453
51. Bellamy W. T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., Grogan T. M., List A. F., Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 2001 97 5 1427 1434 (Pubitemid 32183769)
52. Travaglino E., Benatti C., Malcovati L., Porta M. G. D., Gall A., Bonetti E., Rosti V., Cazzola M., Invernizzi R., Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes European Journal of Haematology 2008 80 3 216 226 (Pubitemid 351253461)
53. Campioni D., Secchiero P., Corallini F., Melloni E., Capitani S., Lanza F., Zauli G., Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes American Journal of Pathology 2005 166 2 557 563 (Pubitemid 40189051)
54. Braun T., Carvalho G., Coquelle A., Vozenin M. C., Lepelley P., Hirsch F., Kiladjian J. J., Ribrag V., Fenaux P., Kroemer G., NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome Blood 2006 107 3 1156 1165 (Pubitemid 43156318)
55. Kerbauy D. M. B., Lesnikov V., Abbasi N., Seal S., Scott B., Joachim Deeg H., NF- B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs) Blood 2005 106 12 3917 3925 (Pubitemid 41739032)
56. Buonamici S., Li D., Chi Y., Zhao R., Wang X., Brace L., Ni H., Saunthararajah Y., Nucifora G., EVI1 induces myelodysplastic syndrome in mice Journal of Clinical Investigation 2004 114 5 713 719 (Pubitemid 39582822)
57. Lin Y. W., Slape C., Zhang Z., Aplan P. D., NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia Blood 2005 106 1 287 295 (Pubitemid 40967204)
58. Grisendi S., Bernardi R., Rossi M., Cheng KE., Khandker L., Manova K., Pandolfi P. P., Role of nucleophosmin in embryonic development and tumorigenesis Nature 2005 437 7055 147 153 (Pubitemid 41613442)
59. Sekeres M. A., Treatment of MDS: something old, something new, something borrowed HematologyAmerican Society of Hematology. Education Program 2009 656 663
60. Kantarjian H., O'Brien S., Cortes J., Wierda W., Faderl S., Garcia-Manero G., Issa J. P., Estey E., Keating M., Freireich E. J., Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years Cancer 2008 113 7 1933 1952
61. Hellstrm-Lindberg E., Malcovati L., Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes Seminars in Hematology 2008 45 1 14 22
62. Tehranchi R., Fadeel B., Forsblom A. M., Christensson B., Samuelsson J., Zhivotovsky B., Hellstrom-Lindberg E., Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors Blood 2003 101 3 1080 1086 (Pubitemid 36139382)
63. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., Nakao S., Nakahata T., Harada M., Murate T., Ozawa K., Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality European Journal of Haematology 2007 78 6 487 494 (Pubitemid 46753591)
64. Metzgeroth G., Dinter D., Schultheis B., Dorn-Beineke A., Lutz K., Leismann O., Hehlmann R., Hastka J., Deferasirox in MDS patients with transfusion-caused iron overloada phase-II study Annals of Hematology 2009 88 4 301 310
65. Sloand E. M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A. M., Keyvanafar K., Lu J., Basu A., Barrett A. J., Young N. S., Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome Blood 2005 106 3 841 851 (Pubitemid 41076423)
66. Selleri C., Maciejewski J. P., Catalano L., Ricci P., Andretta C., Luciano L., Rotoli B., Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies Cancer 2002 95 9 1911 1922 (Pubitemid 35222171)
67. Galm O., Herman J. G., Baylin S. B., The fundamental role of epigenetics in hematopoietic malignancies Blood Reviews 2006 20 1 1 13 (Pubitemid 43106714)
68. Anargyrou K., Vassilakopoulos T. P., Angelopoulou M. K., Terpos E., Incorporating novel agents in the treatment of myelodysplastic syndromes Leukemia Research 2010 34 1 6 17
69. Estey E., Acute myeloid leukemia and myelodysplastic syndromes in older patients Journal of Clinical Oncology 2007 25 14 1908 1915 (Pubitemid 46854425)
70. Estey E. H., Thall P. F., Cortes J. E., Giles F. J., O'Brien S., Pierce S. A., Wang X., Kantarjian H. M., Beran M., Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts Blood 2001 98 13 3575 3583
71. Mufti G., List A. F., Gore S. D., Ho A. Y., Myelodysplastic syndrome Hematology American Society of Hematology. Education Program 2003 176 199
72. Faderl S., Kantarjian H. M., Novel therapies for myelodysplastic syndromes Cancer 2004 101 2 226 241 (Pubitemid 38890824)
73. De Ruijter A. J. M., Van Gennip A. H., Caron H. N., Kemp S., Van Kuilenburg A. B. P., Histone deacetylases (HDACs): characterization of the classical HDAC family Biochemical Journal 2003 370 3 737 749 (Pubitemid 36399066)
74. Xu W. S., Parmigiani R. B., Marks P. A., Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007 26 37 5541 5552 (Pubitemid 47255934)
75. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
76. Herman J. G., Baylin S. B., Gene silencing in cancer in association with promoter hypermethylation New England Journal of Medicine 2003 349 21 2042 2054 (Pubitemid 37448928)
77. Esteller M., Molecular origins of cancer: epigenetics in cancer New England Journal of Medicine 2008 358 11 1148 1159
78. Jones P. A., Baylin S. B., The fundamental role of epigenetic events in cancer Nature Reviews Genetics 2002 3 6 415 428 (Pubitemid 34587077)
79. Santos-Rosa H., Caldas C., Chromatin modifier enzymes, the histone code and cancer European Journal of Cancer 2005 41 16 2381 2402 (Pubitemid 41540617)
80. De La Cruz X., Lois S., Snchez-Molina S., Martnez-Balbs M. A., Do protein motifs read the histone code? BioEssays 2005 27 2 164 175 (Pubitemid 40292388)
81. Schneider-Stock R., Ocker M., Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors The Investigational Drugs Journal 2007 10 8 557 561 (Pubitemid 47186508)
82. Daly K., Shirazi-Beechey S. P., Microarray analysis of butyrate regulated genes in colonic epithelial cells DNA and Cell Biology 2006 25 1 49 62 (Pubitemid 43089752)
83. Gray S. G., Qian C. N., Furge K., Guo X., Teh B. T., Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines International Journal of Oncology 2004 24 4 773 795
84. Roth S. Y., Denu J. M., Allis C. D., Histone acetyltransferases Annual Review of Biochemistry 2001 70 81 120 (Pubitemid 32662206)
85. Marmorstein R., Roth S. Y., Histone acetyltransferases: function, structure, and catalysis Current Opinion in Genetics and Development 2001 11 2 155 161 (Pubitemid 32209199)
86. Witt O., Deubzer H. E., Milde T., Oehme I., HDAC family: what are the cancer relevant targets? Cancer Letters 2009 277 1 8 21
87. Ocker M., Deacetylase inhibitorsfocus on non-histone targets and effects World Journal of Biological Chemistry 2010 1 5 55 61
88. Gao L., Cueto M. A., Asselbergs F., Atadja P., Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family Journal of Biological Chemistry 2002 277 28 25748 25755 (Pubitemid 34951896)
89. Delcuve G. P., Rastegar M., Davie J. R., Epigenetic control Journal of Cellular Physiology 2009 219 2 243 250
90. Spivakov M., Fisher A. G., Epigenetic signatures of stem-cell identity Nature Reviews Genetics 2007 8 4 263 271 (Pubitemid 46439288)
91. Choi J. H., Kwon H. J., Yoon B. I., Kim J. H., Han S. U., Joo H. J., Kim D. Y., Expression profile of histone deacetylase 1 in gastric cancer tissues Japanese Journal of Cancer Research 2001 92 12 1300 1304 (Pubitemid 34036893)
92. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., Iwase H., Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast Breast Cancer Research and Treatment 2005 94 1 11 16 (Pubitemid 41416937)
93. Wilson A. J., Byun D. S., Popova N., Murray L. B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L. H., Mariadason J. M., Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer Journal of Biological Chemistry 2006 281 19 13548 13558 (Pubitemid 43855268)
94. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S. I., Iwase H., HDAC6 expression is correlated with better survival in breast cancer Clinical Cancer Research 2004 10 20 6962 6968 (Pubitemid 39383047)
95. Marks P. A., Xu W. S., Histone deacetylase inhibitors: potential in cancer therapy Journal of Cellular Biochemistry 2009 107 4 600 608
96. Marks P. A., Breslow R., Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nature Biotechnology 2007 25 1 84 90 (Pubitemid 46087907)
97. Marks P. A., Rifkind R. A., Richon V. M., Breslow R., Miller T., Kelly W. K., Histone deacetylases and cancer: causes and therapies Nature Reviews Cancer 2001 1 3 194 202 (Pubitemid 33741894)
98. Minucci S., Pelicci P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nature Reviews Cancer 2006 6 1 38 51 (Pubitemid 43054973)
99. Ocker M., Schneider-Stock R., Histone deacetylase inhibitors: signalling towards p21 International Journal of Biochemistry and Cell Biology 2007 39 7-8 1367 1374 (Pubitemid 47031035)
100. Richon V. M., Sandhoff T. W., Rifkind R. A., Marks P. A., Histone deacetylase inhibitor selectively induces p21WAF1 expressjon and gene-associated histone acetylation Proceedings of the National Academy of Sciences of the United States of America 2000 97 18 10014 10019
101. Gui C. Y., Ngo L., Xu W. S., Richon V. M., Marks P. A., Histone deacetylase (HDAC) inhibitor activation of p21 involves changes in promoter-associated proteins, including HDAC1 Proceedings of the National Academy of Sciences of the United States of America 2004 101 5 1241 1246 (Pubitemid 38182673)
102. Di Fazio P., Schneider-Stock R., Neureiter D., Okamoto K., Wissniowski T., Gahr S., Quint K., Meissnitzer M., Alinger B., Montalbano R., Sass G., Hohenstein B., Hahn E. G., Ocker M., The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis Cellular Oncology 2010 32 4 285 300
103. Zopf S., Neureiter D., Bouralexis S., Abt T., Glaser K. B., Okamoto K., Ganslmayer M., Hahn E. G., Herold C., Ocker M., Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo International Journal of Oncology 2007 31 6 1391 1402
104. Johnstone R. W., Licht J. D., Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003 4 1 13 18 (Pubitemid 36904157)
105. Norris K. L., Lee J. Y., Yao T. P., Acetylation goes global: the emergence of acetylation biology Science Signaling 2009 2 97 e76
106. Smith K. T., Workman J. L., Introducing the acetylome Nature Biotechnology 2009 27 10 917 919
107. Choudhary C., Kumar C., Gnad F., Nielsen M. L., Rehman M., Walther T. C., Olsen J. V., Mann M., Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009 325 5942 834 840
108. Kim S. C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N. V., White M., Yang X. J., Zhao Y., Substrate and functional diversity of lysine acetylation revealed by a proteomics survey Molecular Cell 2006 23 4 607 618 (Pubitemid 44205490)
109. Sadoul K., Boyault C., Pabion M., Khochbin S., Regulation of protein turnover by acetyltransferases and deacetylases Biochimie 2008 90 2 306 312 (Pubitemid 351172566)
110. Prince H. M., Bishton M. J., Harrison S. J., Clinical studies of histone deacetylase inhibitors Clinical Cancer Research 2009 15 12 3958 3969
111. Lane A. A., Chabner B. A., Histone deacetylase inhibitors in cancer therapy Journal of Clinical Oncology 2009 27 32 5459 5468
112. Ryan Q. C., Headlee D., Acharya M., Sparreboom A., Trepel J. B., Ye J., Figg W. D., Hwang K., Chung E. J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E. A., Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma Journal of Clinical Oncology 2005 23 17 3912 3922 (Pubitemid 46218694)
113. Kelly W. K., O'Connor O. A., Krug L. M., Chiao J. H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J. P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P. A., Scher H., Richon V. M., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer Journal of Clinical Oncology 2005 23 17 3923 3931 (Pubitemid 46218695)
114. Rubin E. H., Agrawal N. G. B., Friedman E. J., Scott P., Mazina K. E., Sun L., Du L., Ricker J. L., Frankel S. R., Gottesdiener K. M., Wagner J. A., Iwamoto M., A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer Clinical Cancer Research 2006 12 23 7039 7045 (Pubitemid 44974501)
115. Sandor V., Bakke S., Robey R. W., Kang M. H., Blagosklonny M. V., Bender J., Brooks R., Piekarz R. L., Tucker E., Figg W. D., Chan K. K., Goldspiel B., Fojo A. T., Balcerzak S. P., Bates S. E., Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clinical Cancer Research 2002 8 3 718 728 (Pubitemid 34742100)
116. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W. M., Miller W. H., Rousseau C., Kalita A., Bonfils C., Dubay M., Patterson T. A., Li Z., Besterman J. M., Reid G., Laille E., Martell R. E., Minden M., Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 2008 112 4 981 989
117. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W. G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V. R., Randolph S. S., Hardwick J. S., Reilly J. F., Chen C., Ricker J. L., Secrist J. P., Richon V. M., Frankel S. R., Kantarjian H. M., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 2008 111 3 1060 1066 (Pubitemid 351213383)
118. Lech-Maranda E., Robak E., Korycka A., Robak T., Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity Mini-Reviews in Medicinal Chemistry 2007 7 10 1062 1069 (Pubitemid 47554775)
119. Jenuwein T., Allis C. D., Translating the histone code Science 2001 293 5532 1074 1080 (Pubitemid 32758077)
120. Fandy T. E., Herman J. G., Kerns P., Jiemjit A., Sugar E. A., Choi S. H., Yang A. S., Aucott T., Dauses T., Odchimar-Reissig R., Licht J., McConnell M. J., Nasrallah C., Kim M. K. H., Zhang W., Sun Y., Murgo A., Espinoza-Delgado I., Oteiza K., Owoeye I., Silverman L. R., Gore S. D., Carraway H. E., Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood 2009 114 13 2764 2773
121. Figueroa M. E., Skrabanek L., Li Y., Jiemjit A., Fandy T. E., Paietta E., Fernandez H., Tallman M. S., Greally J. M., Carraway H., Licht J. D., Gore S. D., Melnick A., MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation Blood 2009 114 16 3448 3458
122. Figueroa M. E., Melnick A., Greally J. M., Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias Methods in Molecular Biology 2009 538 395 407
123. Gelsi-Boyer V., Trouplin V., Adlade J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D., Olschwang S., Xerri L., Chaffanet M., Mozziconacci M. J., Vey N., Birnbaum D., Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia British Journal of Haematology 2009 145 6 788 800
124. Gttlicher M., Minucci S., Zhu P., Krmer O. H., Schimpf A., Giavara S., Sleeman J. P., Lo Coco F., Nervi C., Pelicci P. G., Heinzel T., Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO Journal 2002 20 24 6969 6978 (Pubitemid 34062289)
125. Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A., Klein P. S., Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen Journal of Biological Chemistry 2001 276 39 36734 36741
126. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., Germing U., Gattermann N., Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid Blood 2004 104 5 1266 1269 (Pubitemid 39166498)
127. Gore S. D., Weng L. J., Zhai S., Figg W. D., Donehower R. C., Dover G. J., Grever M., Griffin C. A., Grochow L. B., Rowinsky E. K., Zabalena Y., Hawkins A. L., Burks K., Miller C. B., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clinical Cancer Research 2001 7 8 2330 2339 (Pubitemid 32751632)
128. Gore S. D., Weng L. J., Figg W. D., Zhai S., Donehower R. C., Dover G., Grever M. R., Griffin C., Grochow L. B., Hawkins A., Burks K., Zabelena Y., Miller C. B., Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clinical Cancer Research 2002 8 4 963 970 (Pubitemid 35177343)
129. Zhou D.-C., Kim S. H., Ding W., Schultz C., Warrell Jr. R. P., Gallagher R. E., Frequent mutations in the ligand-binding domain of PML-RAR after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo Blood 2002 99 4 1356 1363 (Pubitemid 34547092)
130. Odenike O. M., Alkan S., Sher D., The histone deacetylase inhibitor (HDI) depsipeptide has differential activity in core binding factor AML Blood 2006 108 11 553A
131. Byrd J. C., Marcucci G., Parthun M. R., Xiao J. J., Klisovic R. B., Moran M., Lin T. S., Liu S., Sklenar A. R., Davis M. E., Lucas D. M., Fischer B., Shank R., Tejaswi S. L., Binkley P., Wright J., Chan K. K., Grever M. R., A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood 2005 105 3 959 967 (Pubitemid 40170861)
132. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K., A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clinical Cancer Research 2006 12 15 4628 4635 (Pubitemid 44297814)
133. Garcia-Manero G., Yang H., Sanchez-Gonzalez B., Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome Blood 2005 106 11 785A
134. Gojo I., Jiemjit A., Trepel J. B., Sparreboom A., Figg W. D., Rollins S., Tidwell M. L., Greer J., Eun J. C., Lee M. J., Gore S. D., Sausville E. A., Zwiebel J., Karp J. E., Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 2007 109 7 2781 2790 (Pubitemid 46482071)
135. Fuks F., Burgers W. A., Brehm A., Hughes-Davies L., Kouzarides T., DNA methyltransferase Dnmt1 associates with histone deacetylase activity Nature Genetics 2000 24 1 88 91 (Pubitemid 30041428)
136. Rountree M. R., Bachman K. E., Baylin S. B., DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci Nature Genetics 2000 25 3 269 277 (Pubitemid 30437311)
137. Cameron E. E., Bachman K. E., Myhnen S., Herman J. G., Baylin S. B., Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nature Genetics 1999 21 1 103 107 (Pubitemid 29036293)
138. Jones L. K., Saha V., Chromatin modification, leukaemia and implications for therapy British Journal of Haematology 2002 118 3 714 727 (Pubitemid 35007375)
139. Fahrner J. A., Eguchi S., Herman J. G., Baylin S. B., Dependence of histone modifications and gene expression on DNA hypermethylation in cancer Cancer Research 2002 62 24 7213 7218 (Pubitemid 36025241)
140. Nguyen C. T., Weisenberger D. J., Velicescu M., Gonzales F. A., Lin J. C. Y., Liang G., Jones P. A., Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine Cancer Research 2002 62 22 6456 6461 (Pubitemid 35364106)
141. Neureiter D., Zopf S., Leu T., Dietze O., Hauser-Kronberger C., Hahn E. G., Herold C., Ocker M., Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models Scandinavian Journal of Gastroenterology 2007 42 1 103 116 (Pubitemid 46033053)
142. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., Van Engeland M., Weijenberg M. P., Herman J. G., Baylin S. B., A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer Nature Genetics 2002 31 2 141 149
143. Gore S. D., Baylin S., Sugar E., Carraway H., Miller C. B., Carducci M., Grever M., Galm O., Dauses T., Karp J. E., Rudek M. A., Zhao M., Smith B. D., Manning J., Jiemjit A., Dover G., Mays A., Zwiebel J., Murgo A., Weng L.-J., Herman J. G., Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Research 2006 66 12 6361 6369
144. Garcia-Manero G., Kantarjian H. M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W. G., Ravandi F., Koller C., Xiao L., Faderl S., Estrov Z., Cortes J., O'Brien S., Estey E., Bueso-Ramos C., Fiorentino J., Jabbour E., Issa J. P., Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia Blood 2006 108 10 3271 3279
145. Blum W., Klisovic R. B., Hackanson B., Liu Z., Liu S., Devine H., Vukosavljevic T., Huynh L., Lozanski G., Kefauver C., Plass C., Devine S. M., Heerema N. A., Murgo A., Chan K. K., Grever M. R., Byrd J. C., Marcucci G., Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia Journal of Clinical Oncology 2007 25 25 3884 3891 (Pubitemid 47477265)
146. Soriano A. O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W. G., Ouzounian S., Quezada A., Pierce S., Estey E. H., Issa J. P. J., Kantarjian H. M., Garcia-Manero G., Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 2007 110 7 2302 2308 (Pubitemid 47523148)
147. Maslak P., Chanel S., Camacho L. H., Soignet S., Pandolfi P. P., Guernah I., Warrell R., Nimer S., Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome Leukemia 2006 20 2 212 217 (Pubitemid 43148657)
148. Zhang C., Richon V., Ni X., Talpur R., Duvic M., Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Journal of Investigative Dermatology 2005 125 5 1045 1052
149. Marquard L., Gjerdrum L. M., Christensen I. J., Jensen P. B., Sehested M., Ralfkiaer E., Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma Histopathology 2008 53 3 267 277
150. Ellis L., Pan Y., Smyth G. K., George D. J., McCormack C., Williams-Truax R., Mita M., Beck J., Burris H., Ryan G., Atadja P., Butterfoss D., Dugan M., Culver K., Johnstone R. W., Prince H. M., Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma Clinical Cancer Research 2008 14 14 4500 4510
151. Lindemann R. K., Newbold A., Whitecross K. F., Cluse L. A., Frew A. J., Ellis L., Williams S., Wiegmans A. P., Dear A. E., Scott C. L., Pellegrini M., Wei A., Richon V. M., Marks P. A., Lowe S. W., Smyth M. J., Johnstone R. W., Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2007 104 19 8071 8076 (Pubitemid 47185877)
152. Epping M. T., Wang L., Plumb J. A., Lieb M., Gronemeyer H., Brown R., Bernards R., A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors Proceedings of the National Academy of Sciences of the United States of America 2007 104 45 17777 17782 (Pubitemid 350210911)
153. Fiskus W., Rao R., Fernandez P., Herger B., Yang Y., Chen J., Kolhe R., Mandawat A., Wang Y., Joshi R., Eaton K., Lee P., Atadja P., Peiper S., Bhalla K., Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells Blood 2008 112 7 2896 2905
154. Fantin V. R., Loboda A., Paweletz C. P., Hendrickson R. C., Pierce J. W., Roth J. A., Li L., Gooden F., Korenchuk S., Hou X. S., Harrington E. A., Randolph S., Reilly J. F., Ware C. M., Kadin M. E., Frankel S. R., Richon V. M., Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma Cancer Research 2008 68 10 3785 3794